Sign in
Author
|
Conference
|
Journal
|
Organization
|
Year
|
DOI
Look for results that meet for the following criteria:
since
equal to
before
between
and
Search in all fields of study
Limit my searches in the following fields of study
Agriculture Science
Arts & Humanities
Biology
Chemistry
Computer Science
Economics & Business
Engineering
Environmental Sciences
Geosciences
Material Science
Mathematics
Medicine
Physics
Social Science
Multidisciplinary
Authors
(4558)
Allan Lipton
51
Fred Saad
49
R. Edward Coleman
44
Robert E. Coleman
41
Peter Mesenbrink
36
Conferences
(1)
HHBE
1
Journals
(347)
Reactions Weekly
157
Bone
152
EJC SUPPL
54
EUR UROL SUPPL
50
Inpharma Weekly
39
Keywords
(116)
Subscribe
Academic
Keywords
zoledronic acid
,zoledronic acid
zoledronic acid
Publications: 1,649
|
Citation Count: 11,646
Cumulative
Annual
Definition Context
(3)
Zoledronic acid (ZOL) is a highly potent heterocyclic bisphosphonate which has been shown to inhibit bone resorption in short-term experiments in young growing animals...
S. B. Hornby
,
et al.
Long-Term Zoledronic Acid Treatment Increases Bone Structure and Mecha...
Zoledronic acid is a potent bisphosphonate licensed for the treatment of myeloma and bone metastases from solid tumors. Renal deterioration is the most significant toxicity associated with zoledronic acid...
Raymond S. McDermott
,
et al.
Impact of Zoledronic Acid on Renal Function in Patients With Cancer: C...
Zoledronic acid is a third-generation bisphosphonate that is administered as an annual infusion, and it has some interesting features. After a successful preclinical development program, it has undergone extensive testing in postmenopausal osteoporosis where it has substantial antifracture efficacy at the vertebral, nonvertebral, and hip sites. It has been shown to be effective in reducing vertebral and nonvertebral fractures in patients who had recently suffered a femoral neck fracture, and has demonstrated efficacy in preventing and reversing bone loss in glucocorticoid osteoporosis...
David M. Reid
.
Update on the Use of Zoledronic Acid in the Management of Osteoporosis
Sort by:
Publications
(1649)
Lessons learned from an osteoporosis clinical trial in frail long-term care residents
SL Greenspan
,
D Nace
,
S Perera
,
M Ferchak
,
G Fiorito
,
D Medich
,
K Zukowski
,
D Adams
,
C Lee
,
M Saul
,
NM Resnick
Journal:
Clinical Trials - CLIN TRIALS
, vol. 9, no. 2, pp. 247-256, 2012
Activation of BKCa Channels in Zoledronic Acid-Induced Apoptosis of MDA-MB-231 Breast Cancer Cells
Yu-Guang Ma
,
Wen-Chao Liu
,
Shuo Dong
,
Cheng Du
,
Xiao-Jun Wang
,
Jin-Sheng Li
,
Xiao-Ping Xie
,
Li Wu
,
Da-Chang Ma
,
Zhi-Bin Yu
,
Man-Jiang Xie
Journal:
PLOS One
, vol. 7, no. 5, 2012
MMP-9 from sublethally irradiated tumor promotes Lewis lung carcinoma cell invasiveness and pulmonary metastasis
C H Chou
,
C-M Teng
,
K-Y Tzen
,
Y-C Chang
,
J-H Chen
,
J C-H Cheng
,
JC-H Cheng
Journal:
Oncogene
, vol. 31, no. 4, pp. 458-468, 2012
Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis
A Serpa Neto
,
M Tobias-Machado
,
M A P Esteves
,
M D Senra
,
M L Wroclawski
,
F L A Fonseca
,
R B dos Reis
,
A C L Pompeo
,
A D Giglio
Journal:
Prostate Cancer and Prostatic Diseases - PROSTATE CANCER PROSTATIC DIS
, vol. 15, no. 1, pp. 36-44, 2012
Pharmacoeconomics of Bisphosphonates for Skeletal-Related Event Prevention in Metastatic Non-Breast Solid Tumours
John A. Carter
,
Avani D. Joshi
,
Satyin Kaura
,
Marc F. Botteman
Published in 2012.